WO2001060814A2 - Pyrrole substituted 2-indolinone protein kinase inhibitors - Google Patents

Pyrrole substituted 2-indolinone protein kinase inhibitors Download PDF

Info

Publication number
WO2001060814A2
WO2001060814A2 PCT/US2001/004813 US0104813W WO0160814A2 WO 2001060814 A2 WO2001060814 A2 WO 2001060814A2 US 0104813 W US0104813 W US 0104813W WO 0160814 A2 WO0160814 A2 WO 0160814A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
group
alkyl
compound
aryl
Prior art date
Application number
PCT/US2001/004813
Other languages
English (en)
French (fr)
Other versions
WO2001060814A3 (en
Inventor
Peng Cho Tang
Todd Miller
Xiaoyuan Li
Li Sun
Chung Chen Wei
Shahrzad Shirazian
Congxin Liang
Tomas Vojkovsky
Asaad S. Nematalla
Michael Hawley
Original Assignee
Sugen, Inc.
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001060814(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE122010000004C priority Critical patent/DE122010000004I1/de
Priority to EP01914376A priority patent/EP1255752B1/en
Priority to AU2001239770A priority patent/AU2001239770B2/en
Priority to SK1326-2002A priority patent/SK287142B6/sk
Priority to DE122008000002C priority patent/DE122008000002I1/de
Priority to HU0204433A priority patent/HU228979B1/hu
Priority to DK01914376T priority patent/DK1255752T3/da
Priority to JP2001560198A priority patent/JP3663382B2/ja
Priority to MXPA02008021A priority patent/MXPA02008021A/es
Priority to SI200130778T priority patent/SI1255752T1/sl
Priority to NZ520640A priority patent/NZ520640A/en
Priority to BR0108394-5 priority patent/BRPI0108394B8/pt
Priority to BRPI0117360A priority patent/BRPI0117360B8/pt
Priority to AU3977001A priority patent/AU3977001A/xx
Priority to CA002399358A priority patent/CA2399358C/en
Priority to MEP-2008-530A priority patent/ME00415B/me
Priority to KR1020027010706A priority patent/KR100713960B1/ko
Priority to EA200200862A priority patent/EA005996B1/ru
Priority to UA2002097427A priority patent/UA73976C2/uk
Application filed by Sugen, Inc., Pharmacia & Upjohn Company filed Critical Sugen, Inc.
Priority to IL15112701A priority patent/IL151127A0/xx
Priority to DE60129794T priority patent/DE60129794T2/de
Publication of WO2001060814A2 publication Critical patent/WO2001060814A2/en
Publication of WO2001060814A3 publication Critical patent/WO2001060814A3/en
Priority to NO20023831A priority patent/NO325532B1/no
Priority to IS6501A priority patent/IS2491B/is
Priority to HR20020751A priority patent/HRP20020751B1/xx
Priority to HK03103304A priority patent/HK1051188A1/xx
Priority to CY20071101186T priority patent/CY1108032T1/el
Priority to NL300332C priority patent/NL300332I2/nl
Priority to LU91407C priority patent/LU91407I2/fr
Priority to FR08C0002C priority patent/FR08C0002I2/fr
Priority to LTPA2008002C priority patent/LTC1255752I2/lt
Priority to CY200800004C priority patent/CY2008004I1/el
Priority to NO2008019C priority patent/NO2008019I2/no
Priority to NL300430C priority patent/NL300430I2/nl
Priority to NO2010002C priority patent/NO2010002I2/no
Priority to BE2010C009C priority patent/BE2010C009I2/fr
Priority to LU91657C priority patent/LU91657I2/fr
Priority to CY2010004C priority patent/CY2010004I1/el
Priority to NO2019005C priority patent/NO2019005I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
PCT/US2001/004813 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors WO2001060814A2 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
HU0204433A HU228979B1 (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors
DE60129794T DE60129794T2 (de) 2000-02-15 2001-02-15 Pyrrol substituierte indolin-2-on protein kinase inhibitoren
AU2001239770A AU2001239770B2 (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors
IL15112701A IL151127A0 (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors
DE122008000002C DE122008000002I1 (de) 2000-02-15 2001-02-15 Pyrrol substituierte indolin-2-on protein kinase inhibitoren
JP2001560198A JP3663382B2 (ja) 2000-02-15 2001-02-15 ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
DK01914376T DK1255752T3 (da) 2000-02-15 2001-02-15 Pyrrolsubstituerede 2-indolinonproteinkinaseinhibitorer
EP01914376A EP1255752B1 (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors
MXPA02008021A MXPA02008021A (es) 2000-02-15 2001-02-15 Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas.
SI200130778T SI1255752T1 (sl) 2000-02-15 2001-02-15 S pirolom substituirani zaviralci 2-indolinon protein kinaza
NZ520640A NZ520640A (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors
BR0108394-5 BRPI0108394B8 (pt) 2000-02-15 2001-02-15 inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
BRPI0117360A BRPI0117360B8 (pt) 2000-02-15 2001-02-15 inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
AU3977001A AU3977001A (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors
CA002399358A CA2399358C (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors
MEP-2008-530A ME00415B (me) 2000-02-15 2001-02-15 Pirol supstituisani 2-indol protein kinazni inhibitori
KR1020027010706A KR100713960B1 (ko) 2000-02-15 2001-02-15 피롤 치환 2-인돌리논 단백질 인산화 효소 저해제
EA200200862A EA005996B1 (ru) 2000-02-15 2001-02-15 Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
UA2002097427A UA73976C2 (uk) 2000-02-15 2001-02-15 Заміщені піролом 2-індолінони, фармацевтична композиція, спосіб модуляції каталітичної активності протеїнкінази та спосіб лікування або профілактики захворювання, пов'язаного з протеїнкіназою
DE122010000004C DE122010000004I1 (de) 2000-02-15 2001-02-15 Pyrrol substituierte indolin-2-on protein kinase inhibitoren
SK1326-2002A SK287142B6 (sk) 2000-02-15 2001-02-15 Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
IS6501A IS2491B (is) 2000-02-15 2002-08-13 Pýrról-setnir 2-indólínón prótín kínasa hindrar
NO20023831A NO325532B1 (no) 2000-02-15 2002-08-13 Pyrrolsubstituerte 2-indolinoner, farmasoytisk preparat omfattende slike, fremgangsmate for a modulere den katalytiske aktiviteten til en proteinkinase in vitro basert pa bruk av slike forbindelser, samt anvendelse av slike forbindelser til fremstilling av medikamenter for behandling av sykdommer.
HR20020751A HRP20020751B1 (en) 2000-02-15 2002-09-13 Pyrrole substituted 2-indolinone protein kinase inhibitors
HK03103304A HK1051188A1 (en) 2000-02-15 2003-05-12 Pyrrole substituted 2-indolinone protein kinase inhibitors
CY20071101186T CY1108032T1 (el) 2000-02-15 2007-09-13 Πυρρολο υποκατεστημενης 2-ινδολινονης αναστολεις κινασης πρωτεϊνης
NL300332C NL300332I2 (nl) 2000-02-15 2008-01-08 Met pyrrol gesubstitueerde 2-indolinon proteine kinase remmers
LU91407C LU91407I2 (fr) 2000-02-15 2008-01-09 Sunitinib optionnellement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel l-malate (sutent)
FR08C0002C FR08C0002I2 (fr) 2000-02-15 2008-01-15 Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
LTPA2008002C LTC1255752I2 (lt) 2000-02-15 2008-02-04 Pirolu pakeisti 2-indolinono proteinkinazės inhibitoriai
CY200800004C CY2008004I1 (el) 2000-02-15 2008-02-08 Πυρρολο υποκατεστημενης 2-ινδολινονης αναστολεις κινασης πρωτεϊνης
NO2008019C NO2008019I2 (no) 2000-02-15 2008-12-08 Sunitinib
NL300430C NL300430I2 (nl) 2000-02-15 2009-12-29 Met pyrrol gesubstitueerde 2-indolinon proteine kinase remmers.
NO2010002C NO2010002I2 (no) 2000-02-15 2010-02-09 Toceranibfosfat.
BE2010C009C BE2010C009I2 (US06573293-20030603-C00090.png) 2000-02-15 2010-02-11
LU91657C LU91657I2 (fr) 2000-02-15 2010-03-03 Tocéranibe et ses dérivés pharmaceutiquement acceptables (PALLADIA®)
CY2010004C CY2010004I1 (el) 2000-02-15 2010-03-09 Πυρρολο υποκατεστημενης 2-ινδολινονης αναστολεις κινασης πρωτεϊνης
NO2019005C NO2019005I1 (no) 2000-02-15 2019-02-05 N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18271000P 2000-02-15 2000-02-15
US60/182,710 2000-02-15
US21642200P 2000-07-06 2000-07-06
US60/216,422 2000-07-06
US24353200P 2000-10-27 2000-10-27
US60/243,532 2000-10-27

Publications (2)

Publication Number Publication Date
WO2001060814A2 true WO2001060814A2 (en) 2001-08-23
WO2001060814A3 WO2001060814A3 (en) 2002-01-24

Family

ID=27391578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004813 WO2001060814A2 (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors

Country Status (43)

Country Link
US (4) US6573293B2 (US06573293-20030603-C00090.png)
EP (1) EP1255752B1 (US06573293-20030603-C00090.png)
JP (1) JP3663382B2 (US06573293-20030603-C00090.png)
KR (1) KR100713960B1 (US06573293-20030603-C00090.png)
CN (1) CN1329390C (US06573293-20030603-C00090.png)
AR (1) AR034118A1 (US06573293-20030603-C00090.png)
AT (1) ATE369359T1 (US06573293-20030603-C00090.png)
AU (2) AU3977001A (US06573293-20030603-C00090.png)
BE (1) BE2010C009I2 (US06573293-20030603-C00090.png)
BG (1) BG65764B1 (US06573293-20030603-C00090.png)
BR (2) BRPI0108394B8 (US06573293-20030603-C00090.png)
CA (1) CA2399358C (US06573293-20030603-C00090.png)
CO (1) CO5280092A1 (US06573293-20030603-C00090.png)
CR (2) CR20120007A (US06573293-20030603-C00090.png)
CY (3) CY1108032T1 (US06573293-20030603-C00090.png)
CZ (1) CZ303705B6 (US06573293-20030603-C00090.png)
DE (3) DE122010000004I1 (US06573293-20030603-C00090.png)
DK (1) DK1255752T3 (US06573293-20030603-C00090.png)
EA (1) EA005996B1 (US06573293-20030603-C00090.png)
ES (1) ES2290117T3 (US06573293-20030603-C00090.png)
FR (1) FR08C0002I2 (US06573293-20030603-C00090.png)
HK (1) HK1051188A1 (US06573293-20030603-C00090.png)
HR (1) HRP20020751B1 (US06573293-20030603-C00090.png)
HU (1) HU228979B1 (US06573293-20030603-C00090.png)
IL (1) IL151127A0 (US06573293-20030603-C00090.png)
IS (1) IS2491B (US06573293-20030603-C00090.png)
LT (1) LTC1255752I2 (US06573293-20030603-C00090.png)
LU (2) LU91407I2 (US06573293-20030603-C00090.png)
ME (1) ME00415B (US06573293-20030603-C00090.png)
MX (1) MXPA02008021A (US06573293-20030603-C00090.png)
MY (1) MY130363A (US06573293-20030603-C00090.png)
NL (2) NL300332I2 (US06573293-20030603-C00090.png)
NO (4) NO325532B1 (US06573293-20030603-C00090.png)
NZ (1) NZ520640A (US06573293-20030603-C00090.png)
PE (1) PE20011083A1 (US06573293-20030603-C00090.png)
PL (1) PL211834B1 (US06573293-20030603-C00090.png)
PT (1) PT1255752E (US06573293-20030603-C00090.png)
RS (1) RS50444B (US06573293-20030603-C00090.png)
SI (1) SI1255752T1 (US06573293-20030603-C00090.png)
SK (1) SK287142B6 (US06573293-20030603-C00090.png)
TW (1) TWI306860B (US06573293-20030603-C00090.png)
UA (1) UA73976C2 (US06573293-20030603-C00090.png)
WO (1) WO2001060814A2 (US06573293-20030603-C00090.png)

Cited By (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002551A1 (en) * 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
WO2002066463A1 (en) * 2001-02-15 2002-08-29 Pharmacia & Upjohn Company 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
US6451838B1 (en) 2000-05-24 2002-09-17 Pharmacia & Upjohn Company 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
WO2003016305A1 (en) 2001-08-15 2003-02-27 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
WO2003022815A1 (en) * 2001-09-10 2003-03-20 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
WO2003031438A1 (en) * 2001-10-10 2003-04-17 Sugen, Inc. 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2003070725A2 (en) * 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Process for preparing indolinone derivatives
WO2003097854A2 (en) * 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
US6677368B2 (en) * 2000-12-20 2004-01-13 Sugen, Inc. 4-aryl substituted indolinones
US6686362B2 (en) 2001-12-27 2004-02-03 Theravance, Inc. Indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2004045523A2 (en) * 2002-11-15 2004-06-03 Sugen, Inc. Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
EP1444204A1 (en) * 2001-10-22 2004-08-11 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
EP1446117A2 (en) * 2001-10-26 2004-08-18 Sugen, Inc. Treatment of acute myeloid leukemia with indolinone compounds
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US6831175B2 (en) 2001-12-13 2004-12-14 Abbott Laboratories Kinase inhibitors
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
EP1581309A2 (en) * 2002-11-15 2005-10-05 Exelixis, Inc. Kinase modulators
EP1599200A2 (en) * 2003-02-24 2005-11-30 PHARMACIA & UPJOHN COMPANY Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
WO2006004545A1 (en) * 2004-07-07 2006-01-12 Forskarpatent I Syd Ab Tamoxifen response in pre-and postmenopausal breast cancer patients
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
WO2007034272A1 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Solid salt forms of a pyrrole substituted 2-indolinone
WO2007084786A1 (en) 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
EP1814545A2 (en) * 2004-11-09 2007-08-08 Irm, Llc Compounds and compositions as protein kinase inhibitors
WO2007124288A1 (en) 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of cdc7
DE102006024834A1 (de) * 2006-05-24 2007-11-29 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendung
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
EP1893194A1 (en) * 2005-05-26 2008-03-05 The Scripps Research Institute Enhanced indolinone based protein kinase inhibitors
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
EP1971333A2 (en) * 2005-12-29 2008-09-24 The Scripps Research Institute Amino acid derivatives of indolinone based protein kinase inhibitors
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2008145398A1 (en) * 2007-06-01 2008-12-04 Pfizer Italia S.R.L. 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
WO2009047563A1 (en) 2007-10-11 2009-04-16 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
WO2009067686A2 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
WO2009082687A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009100929A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
WO2009104021A2 (en) * 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2130829A1 (en) * 2006-11-06 2009-12-09 Theravalues Corporation Novel hydroxyindole derivative
WO2009156128A1 (en) * 2008-06-24 2009-12-30 Ratiopharm Gmbh Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide
WO2009157011A1 (en) * 2008-06-23 2009-12-30 Natco Pharma Limited Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
DE102008031038A1 (de) 2008-06-30 2009-12-31 Alexander Priv.-Doz. Dr. Dömling Sutent zur Anwendung in der Organtransplantation
WO2010004339A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
WO2010023473A2 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
WO2010023474A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel polymorphs of sunitinib and processes for their preparation
US7683057B2 (en) 2006-09-15 2010-03-23 Tyrogenex, Inc. Kinase inhibitor compounds
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2197878A2 (en) * 2007-09-06 2010-06-23 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
WO2010073034A1 (en) 2008-12-22 2010-07-01 Astrazeneca Ab Pyrimidine indole derivatives for treating cancer
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2010076805A2 (en) 2009-01-02 2010-07-08 Hetero Research Foundation Novel polymorphs of sunitinib malate
US7772216B2 (en) 2001-10-22 2010-08-10 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010091150A1 (en) 2009-02-05 2010-08-12 Immunogen, Inc. Novel benzodiazepine derivatives
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010103094A1 (en) 2009-03-13 2010-09-16 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2010108665A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
WO2010118986A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2010136458A1 (en) * 2009-05-27 2010-12-02 Ratiopharm Gmbh Process for the preparation of n-[2-diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2266974A1 (en) 2005-05-23 2010-12-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts
WO2011000905A1 (en) 2009-07-02 2011-01-06 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP2277595A2 (en) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP2281822A1 (fr) * 2009-08-04 2011-02-09 Les Laboratoires Servier Nouveaux dérivés dihydroindolones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US7901894B2 (en) 1999-01-13 2011-03-08 The Research Foundation Of State University Of New York Kinase inhibitors
US7902189B2 (en) * 2006-08-23 2011-03-08 Astrazeneca Ab Compounds
EP2292613A1 (en) * 2008-05-23 2011-03-09 Shanghai Institute of Pharmaceutical Industry Dihydroindolinone derivatives
WO2011029807A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
US7932262B2 (en) 2006-04-06 2011-04-26 Novartis Ag Quinazolines for PDK1 inhibition
WO2011048082A1 (en) 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
WO2011068233A1 (en) 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
US7973160B2 (en) 2000-10-20 2011-07-05 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic derivatives
EP2357202A1 (en) 2006-04-10 2011-08-17 AstraZeneca AB Targeted binding agents directed to Upar and uses thereof
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP2359829A1 (en) 2003-04-29 2011-08-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
WO2011101429A1 (en) 2010-02-22 2011-08-25 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
EP2361905A1 (en) 2005-05-18 2011-08-31 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
WO2011107585A1 (en) 2010-03-04 2011-09-09 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
WO2011110199A1 (en) 2010-03-10 2011-09-15 Synthon B.V. A process for amidation of pyrrole carboxylate compounds
US8034812B2 (en) 2006-08-04 2011-10-11 Takeda Pharmaceutical Company Limited Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof
WO2011134831A1 (en) 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
US8058474B2 (en) 2003-11-11 2011-11-15 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
WO2011154737A1 (en) 2010-06-11 2011-12-15 Astrazeneca Ab Morpholino pyrimidines and their use in therapy
US8084621B2 (en) 2006-12-04 2011-12-27 Jiangsu Simcere Pharmaceutical R&D Co. Ltd. 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof
WO2012000970A1 (en) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2011104555A3 (en) * 2010-02-25 2012-02-02 Generics [Uk] Limited Process for the preparation of sunitinib malate form i
WO2012016970A1 (en) 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor
EP2420514A1 (en) 2006-08-03 2012-02-22 MedImmune Limited Targeted binding agents directed to PDGFR-alpha and uses thereof
WO2012022681A2 (en) 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
US8143258B2 (en) 2008-12-02 2012-03-27 Takeda Pharmaceutical Company Limited Benzothiazole compounds useful for Raf inhibition
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2012074761A1 (en) 2010-12-03 2012-06-07 Eli Lilly And Company Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
US8211429B2 (en) 2005-11-08 2012-07-03 Genetech, Inc. Neuropilin antagonists
EP2476667A2 (en) 2003-02-26 2012-07-18 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
WO2012110774A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
WO2012112708A1 (en) 2011-02-15 2012-08-23 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
CN102653521A (zh) * 2012-04-27 2012-09-05 首都师范大学 吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
WO2012136622A1 (en) 2011-04-04 2012-10-11 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8329682B2 (en) 2007-05-14 2012-12-11 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
WO2013014162A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
WO2013041652A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
WO2013050508A1 (en) 2011-10-07 2013-04-11 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013092854A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
US20130331425A1 (en) * 2010-12-23 2013-12-12 Nektar Therapeutics Polymer-sunitinib conjugates
WO2013185115A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US8618309B2 (en) 2008-07-24 2013-12-31 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
EP2690101A1 (en) 2007-12-19 2014-01-29 Genentech, Inc. 5-Anilinoimidazopyridines and Methods of Use
WO2014026243A1 (en) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2014093383A1 (en) 2012-12-14 2014-06-19 Arrien Pharmaceuticals Llc Substituted 1h-pyrrolo [2,3-b] pyridine and 1h-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors
EP2762475A1 (en) 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014140644A1 (en) 2013-03-15 2014-09-18 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Chemical entities
US8846953B2 (en) 2010-11-01 2014-09-30 Scinopharm Taiwan, Ltd. Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
WO2014160401A1 (en) * 2013-03-13 2014-10-02 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US8993249B2 (en) 2010-07-09 2015-03-31 Genentech, Inc. Anti-neuropilin antibodies and methods of use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2927244A1 (en) 2008-09-19 2015-10-07 MedImmune, LLC Antibodies directed to DLL4 and uses thereof
WO2016198507A1 (en) 2015-06-09 2016-12-15 Monash University Aryl sulfonohydrazides
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9585850B2 (en) 2011-12-23 2017-03-07 Duke University Methods of treatment using arylcyclopropylamine compounds
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2017132617A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
EP3279215A1 (en) 2009-11-24 2018-02-07 MedImmune Limited Targeted binding agents against b7-h1
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2018106606A1 (en) 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
EP3409278A1 (en) 2011-07-21 2018-12-05 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
US10220020B2 (en) 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
WO2019055909A1 (en) 2017-09-18 2019-03-21 Sutro Biopharma, Inc. ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
US10259791B2 (en) 2014-08-28 2019-04-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
WO2019083365A1 (en) 2017-10-25 2019-05-02 Universiteit Leiden VECTORS OF ADMINISTRATION
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
EP3545956A1 (en) 2013-04-18 2019-10-02 Arrien Pharmaceuticals LLC 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h- pyrrolo[2,3-b]pyrazine dual itk and jak3 kinase inhibitors
WO2019236496A1 (en) 2018-06-04 2019-12-12 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2020002587A1 (en) 2018-06-28 2020-01-02 Ctxt Pty Limited Compounds
EP3590932A1 (en) 2013-03-14 2020-01-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
US10544144B2 (en) 2016-06-06 2020-01-28 Shanghai Allist Pharmaceutical And Medical Technol Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof
WO2020060944A1 (en) 2018-09-17 2020-03-26 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
US10766865B2 (en) 2012-10-16 2020-09-08 Sumitomo Dainippon Pharma Oncology, Inc. PKM2 modulators and methods for their use
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
US10835537B2 (en) 2015-08-03 2020-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of cancer
WO2021037219A1 (zh) 2019-08-31 2021-03-04 上海奕拓医药科技有限责任公司 用于fgfr抑制剂的吡唑类衍生物及其制备方法
EP3789027A1 (en) 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11090386B2 (en) 2015-02-25 2021-08-17 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP4000619A1 (en) 2013-12-06 2022-05-25 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US11547705B2 (en) 2015-03-04 2023-01-10 Merck Sharp & Dohme Llc Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
WO2024006542A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
EP4335439A2 (en) 2018-06-20 2024-03-13 Ctxt Pty Ltd Compounds

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
BRPI0108394B8 (pt) * 2000-02-15 2021-05-25 Upjohn Co inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP1247809A3 (en) * 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20030080191A1 (en) * 2001-10-26 2003-05-01 Allen Lubow Method and apparatus for applying bar code information to products during production
EP1466297A4 (en) * 2001-12-17 2005-10-19 Int Barcode Corp AS A SINGLE CODE, DOUBLE-SIDED CODE
US20050131733A1 (en) * 2001-12-17 2005-06-16 Allen Lubow Sealable individual bar coded packets
ITMI20021620A1 (it) * 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale
WO2004016211A2 (en) * 2002-08-08 2004-02-26 Vanderbilt University Pi3k antagonists as radiosensitizers
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
ATE508747T1 (de) * 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
DE10334582A1 (de) * 2003-07-28 2005-02-24 Basf Ag Verfahren zur Herstellung von Maleinsäureanhydrid
JP4933259B2 (ja) * 2003-10-02 2012-05-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ピロール置換インドリノン化合物の塩および多形
CA2542638A1 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
AU2004294981A1 (en) * 2003-11-26 2005-06-16 The Scripps Research Institute Advanced indolinone based protein kinase inhibitors
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
US20050152943A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
ATE463486T1 (de) * 2004-08-26 2010-04-15 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
CN100432071C (zh) * 2004-11-05 2008-11-12 中国科学院上海药物研究所 取代1h－吲哚－2－酮类化合物及其制备方法和用途
RU2007135167A (ru) * 2005-03-23 2009-03-27 Пфайзер Продактс Инк. (Us) Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
BRPI0609957A2 (pt) * 2005-05-12 2010-05-11 Pfizer uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
PL1933871T3 (pl) 2005-09-07 2013-09-30 Amgen Fremont Inc Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do recepora aktywiny-1
EP1949902B1 (en) * 2005-11-07 2012-06-27 Eisai R&D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
WO2007132307A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008008981A1 (en) 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
JP4523073B2 (ja) 2007-02-06 2010-08-11 ファイザー・インク 癌を治療するためのＨＳＰ−９０阻害剤としての２−アミノ−５，７−ジヒドロ−６Ｈ−ピロロ［３，４−ｄ］ピリミジン誘導体
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20090042906A1 (en) * 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
US20090062368A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sunitinib
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
US8389562B2 (en) * 2007-12-12 2013-03-05 Medichem, S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
CN101255154B (zh) * 2008-02-18 2011-09-07 靳广毅 一种取代的2-吲哚啉酮衍生物和制备方法及其应用
WO2009124037A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
US8263547B2 (en) * 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
SI2313371T1 (sl) * 2008-06-13 2013-02-28 Medichem, S.A. Postopek za pripravo soli 3-pirol substituirane 2-indolinonske jabolčne kisline
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
EP2294184A4 (en) 2008-06-30 2013-03-06 Mesoblast Inc TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
CA2729745A1 (en) * 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
AU2009265360A1 (en) * 2008-07-02 2010-01-07 Generics [Uk] Limited Preparation of 3-pyrrole substituted 2-indolinone derivatives
WO2010010454A2 (en) 2008-07-24 2010-01-28 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
CA2735006A1 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
MX2011002498A (es) * 2008-09-05 2011-08-04 Imp Innovations Ltd Derivados de isatina para uso como agentes de formacion de imagenes in vivo.
AR073807A1 (es) * 2008-10-10 2010-12-01 Medichem Sa Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
KR102187034B1 (ko) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
US9265764B2 (en) * 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
EP2477978A1 (en) 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Salts of sunitinib
US20120271056A1 (en) 2009-11-12 2012-10-25 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011095802A1 (en) 2010-02-02 2011-08-11 Generics [Uk] Limited Hplc method for analyzing sunitinib
WO2011100325A2 (en) * 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
AU2011222470A1 (en) 2010-03-04 2012-09-27 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
CA2793359A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
EP2550263A4 (en) 2010-03-23 2013-07-24 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
WO2011128699A2 (en) * 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2011138565A1 (fr) 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
EP2392324A1 (en) 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012059941A1 (en) * 2010-11-04 2012-05-10 Ind-Swift Laboratories Limited Process for preparation of sunitinib malate and salts thereof
EP2640384A1 (en) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
US8630703B2 (en) 2011-03-09 2014-01-14 Technion Research & Development Foundation Limited Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
CN102115469A (zh) * 2011-03-21 2011-07-06 浙江大学 吲哚啉-2-酮类衍生物的制备和用途
KR20140027972A (ko) 2011-04-08 2014-03-07 베타 파마, 인크. 신규 인돌리논 단백질 키나제 억제제
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
CN102898402B (zh) * 2011-04-26 2016-01-20 北京大学 一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用
CN102499917B (zh) 2011-10-25 2014-12-17 澳门大学 吲哚酮类化合物在制备神经保护药物中的应用
CN103130774B (zh) * 2011-11-22 2016-06-22 齐鲁制药有限公司 具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
CN102491932A (zh) * 2011-12-26 2012-06-13 天津科技大学 一种3-吲哚啉酮类衍生物及其制备方法及其应用
WO2013140232A1 (en) 2012-03-23 2013-09-26 Laurus Labs Private Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
IN2014MN02105A (US06573293-20030603-C00090.png) 2012-04-20 2015-09-11 Annji Pharm Co Ltd
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
RU2609651C2 (ru) 2012-05-04 2017-02-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN104119321B (zh) * 2013-04-28 2017-09-08 齐鲁制药有限公司 二氢吲哚酮衍生物的二马来酸盐及其多晶型物
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
CA2838587A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
MY182168A (en) 2013-11-01 2021-01-18 Pfizer Vectors for expression of prostate-associated antigens
CN104829596B (zh) 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
CN103923014A (zh) * 2014-05-05 2014-07-16 宁夏宝马药业有限公司 环肌酸制备方法
EP3177289A4 (en) 2014-08-08 2018-03-21 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
BR112017022666A8 (pt) 2015-04-20 2022-10-18 Tolero Pharmaceuticals Inc Preparando resposta à alvocidib por perfilamento mitocondrial
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
ES2921350T3 (es) 2015-05-18 2022-08-24 Sumitomo Pharma Oncology Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
JP2018536017A (ja) 2015-09-22 2018-12-06 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための化合物及び組成物
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
WO2017083779A1 (en) 2015-11-12 2017-05-18 Graybug Vision, Inc. Aggregating microparticles for therapy
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CN110167924A (zh) 2016-10-28 2019-08-23 西奈山伊坎医学院 用于治疗ezh2介导的癌症的组合物和方法
CN110267659A (zh) 2016-12-08 2019-09-20 西奈山伊坎医学院 用于治疗cdk4/6介导的癌症的组合物和方法
AU2017379847B2 (en) 2016-12-19 2022-05-26 Sumitomo Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
CN106916143B (zh) * 2017-03-14 2019-09-27 哈尔滨医科大学 一种预防和治疗冠心病的药物及其应用
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
JP2020519585A (ja) 2017-05-10 2020-07-02 グレイバグ ビジョン インコーポレイテッド 医学療法のための延長放出マイクロ粒子及びその懸濁液
JP2021515013A (ja) 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
WO2020227325A1 (en) 2019-05-06 2020-11-12 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of hpk1
CN111233841A (zh) * 2020-03-17 2020-06-05 湖北扬信医药科技有限公司 一种舒尼替尼有关物质及其制备方法和用途
WO2023278424A1 (en) * 2021-06-28 2023-01-05 The Regents Of The University Of California Methods for treating and ameliorating t cell related diseases
CN113717159A (zh) * 2021-09-16 2021-11-30 中国药科大学 吲哚酮类化合物及其药物组合物、制备方法及用途
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2024017372A1 (zh) * 2022-07-22 2024-01-25 成都百裕制药股份有限公司 一种吲哚酮衍生物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US5886020A (en) * 1995-06-07 1999-03-23 Sugen, Inc. 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
WO1999061422A1 (en) * 1998-05-29 1999-12-02 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2000035908A1 (en) * 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
WO2000038519A1 (en) * 1998-12-31 2000-07-06 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL230368A (US06573293-20030603-C00090.png) 1957-08-19
DE878539C (de) 1939-08-17 1953-06-05 Hoechst Ag Verfahren zur Herstellung von Methinfarbstoffen
BE507136A (US06573293-20030603-C00090.png) 1950-11-18
BE553661A (US06573293-20030603-C00090.png) 1955-12-23
BE558210A (US06573293-20030603-C00090.png) 1956-06-08
NL251055A (US06573293-20030603-C00090.png) 1959-04-29
FR1398224A (fr) 1964-05-06 1965-05-07 Ici Ltd Procédé de teinture de matières textiles de polyacrylonitrile
US3308134A (en) 1965-10-22 1967-03-07 Mcneilab Inc Spiro(indan-2, 3'-indoline)-1, 2'-diones
US3551571A (en) 1967-05-19 1970-12-29 Endo Lab Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones
US3564016A (en) 1968-03-07 1971-02-16 Endo Lab Method of decarbonylation
US4070366A (en) 1968-06-12 1978-01-24 Canadian Patents & Development Limited Alkylation process
FR1599772A (US06573293-20030603-C00090.png) 1968-09-17 1970-07-20
US3922163A (en) 1970-01-30 1975-11-25 Upjohn Co Organic compounds and process
US3715364A (en) 1970-12-28 1973-02-06 Merck & Co Inc Nitroimidazole carboxamides
DE2159363A1 (de) 1971-11-30 1973-06-14 Bayer Ag Antimikrobielle mittel
DE2159362A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159360A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159361A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB1384599A (en) 1972-05-04 1975-02-19 Colgate Palmolive Co Coloured detergent compositions
US3880871A (en) 1973-09-27 1975-04-29 Squibb & Sons Inc Isothiocyanophenyl substituted imidazoles
US4002643A (en) 1975-06-27 1977-01-11 Mcneil Laboratories, Inc. Preparation of β-acyl pyrroles
US4002749A (en) 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
US4053613A (en) 1975-09-17 1977-10-11 E. R. Squibb & Sons, Inc. 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
DE2855306A1 (de) 1978-12-21 1980-07-10 Boehringer Sohn Ingelheim Mittel zur senkung der herzfrequenz
GR73560B (US06573293-20030603-C00090.png) 1979-02-24 1984-03-15 Pfizer
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4343923A (en) 1980-08-07 1982-08-10 Armstrong World Industries, Inc. Process for reducing the acid dye uptake of polyamide textile materials with N-acylimidazole compound
CH646956A5 (de) 1981-12-15 1984-12-28 Ciba Geigy Ag Imidazolide.
EP0095285A1 (en) 1982-05-21 1983-11-30 Sumitomo Chemical Company, Limited N-acylimidazoles, their production and use
US4493642A (en) 1982-12-27 1985-01-15 Bogdon Glendon J Orthodontic device and associated orthodontic method
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4489089A (en) 1983-04-06 1984-12-18 American Cyanamid Company Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides
EP0124482B1 (de) 1983-04-29 1989-11-08 Ciba-Geigy Ag Neue Imidazolide und deren Verwendung als Härter für Polyepoxidverbindungen
DE3415138A1 (de) 1984-04-21 1985-10-31 Basf Ag, 6700 Ludwigshafen N-(azolylcarbamoyl)-hydroxylamine und diese enthaltende fungizide
DE3426419A1 (de) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4560700A (en) 1985-02-08 1985-12-24 Merrell Dow Pharmaceuticals Inc. Pyrrole-3-carboxylate cardiotonic agents
JPH078851B2 (ja) 1985-07-29 1995-02-01 鐘淵化学工業株式会社 ３−フエニルチオメチルスチレン誘導体
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4853404A (en) 1986-10-13 1989-08-01 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives composition and use
US5089516A (en) 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5202341A (en) 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
DE3874257T2 (de) 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
US5043348A (en) 1987-04-24 1991-08-27 Cassella Aktiengesellschaft Pyrrolealdehydes, their preparation and their use
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3808071A1 (de) 1988-03-11 1989-09-21 Basf Ag Verfahren zur herstellung von acylierten imidazolen
US4868304A (en) 1988-05-27 1989-09-19 Iowa State University Research Foundation, Inc. Synthesis of nitrogen heterocycles
JPH06104658B2 (ja) 1988-06-23 1994-12-21 三菱化成株式会社 ピロールカルボン酸誘導体
CA1339784C (en) 1988-06-23 1998-03-31 Shinya Inoue Pyrrolecarboxylic acid derivatives
GB8816944D0 (en) 1988-07-15 1988-08-17 Sobio Lab Compounds
DE3824658A1 (de) 1988-07-15 1990-01-18 Schering Ag N-hetaryl-imidazolderivate
US5084280A (en) 1988-12-15 1992-01-28 Chapman Chemical Company Wood preservation composition and method
DE3902439A1 (de) 1989-01-27 1990-08-02 Basf Ag Pflanzenschuetzende mittel auf basis von 1-aryl- bzw. 1-hetarylimidazolcarbonsaeureestern
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
ES2110965T3 (es) 1989-07-25 1998-03-01 Taiho Pharmaceutical Co Ltd Derivado de oxoindol.
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
CA2032421A1 (en) 1989-12-20 1991-06-21 Mitsubishi Chemical Corporation Pyrrolealdehyde derivative
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2012634A1 (en) 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
IT1247509B (it) 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9115160D0 (en) 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5124347A (en) 1991-07-31 1992-06-23 Warner-Lambert Co. 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents
CZ290470B6 (cs) 1991-10-18 2002-07-17 Monsanto Technology Llc 5 či 6 členné aromáty jako fungicidy pro kontrolu stéblolamu rostlin, způsob kontroly a fungicidní směs k provedení tohoto způsobu
US5389661A (en) 1991-12-05 1995-02-14 Warner-Lambert Company Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
US5322950A (en) 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2689397A1 (fr) 1992-04-01 1993-10-08 Adir Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments.
DE4211531A1 (de) 1992-04-06 1993-10-07 Cassella Ag Verfahren zur Herstellung von Pyrrolderivaten
FR2694004B1 (fr) 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
JP3507124B2 (ja) 1993-05-26 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造法
DE59402281D1 (de) 1993-06-28 1997-05-07 Bayer Ag Massefärben von Kunststoffen
US5332736A (en) 1993-11-01 1994-07-26 Ortho Pharmaceutical Corporation Anti-convulsant aroyl aminoacylpyrroles
US5610173A (en) 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5786488A (en) 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
JP3246712B2 (ja) 1995-11-15 2002-01-15 株式会社トクヤマ エテニルアミド化合物の製造方法
EP0788890A1 (en) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Dyes and dye-donor elements for thermal dye transfer recording
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
CA2262847C (en) 1996-08-01 2007-06-05 Merckle Gmbh Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
CZ20012113A3 (cs) 1998-12-14 2001-11-14 Cellegy Pharmaceuticals, Inc. Prostředky a způsoby pro léčbu onemocnění anorektální oblasti
US6284894B1 (en) 1998-12-18 2001-09-04 Nycomed Imaging As Preparation of allylic aromatic compounds
MXPA02006263A (es) * 1999-12-22 2004-02-26 Sugen Inc Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona.
BRPI0108394B8 (pt) * 2000-02-15 2021-05-25 Upjohn Co inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1296975A1 (en) * 2000-06-30 2003-04-02 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
EP1349852A2 (en) * 2000-12-20 2003-10-08 Sugen, Inc. 4-(hetero)aryl substituted indolinones

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886020A (en) * 1995-06-07 1999-03-23 Sugen, Inc. 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1999061422A1 (en) * 1998-05-29 1999-12-02 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2000035908A1 (en) * 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
WO2000038519A1 (en) * 1998-12-31 2000-07-06 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI SUN ET AL.: "Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novelclass of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases" JOURNAL OF MEDICINAL CHEMISTRY., vol. 41, no. 14, - 1998 pages 2588-2603, XP002181002 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 *

Cited By (354)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US7901894B2 (en) 1999-01-13 2011-03-08 The Research Foundation Of State University Of New York Kinase inhibitors
US7053113B2 (en) 2000-05-24 2006-05-30 Sugen, Inc. Mannich base prodrugs of 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives
US7112603B2 (en) 2000-05-24 2006-09-26 Agouron Pharmaceuticals, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6716870B2 (en) 2000-05-24 2004-04-06 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6710067B2 (en) 2000-05-24 2004-03-23 Sugen Incorporated Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6482848B2 (en) 2000-05-24 2002-11-19 Sugen Incorporated Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6451838B1 (en) 2000-05-24 2002-09-17 Pharmacia & Upjohn Company 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US7008943B2 (en) 2000-05-24 2006-03-07 Pharmacia & Upjohn Company 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US7071332B2 (en) 2000-06-02 2006-07-04 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
WO2002002551A1 (en) * 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US7053086B2 (en) 2000-06-30 2006-05-30 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US8372981B2 (en) 2000-10-20 2013-02-12 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic derivatives
US7973160B2 (en) 2000-10-20 2011-07-05 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic derivatives
US6861418B2 (en) 2000-12-20 2005-03-01 Sugen, Inc. 4-aryl substituted indolinones
US6677368B2 (en) * 2000-12-20 2004-01-13 Sugen, Inc. 4-aryl substituted indolinones
AP1718A (en) * 2001-02-15 2007-01-30 Sugen Inc 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
WO2002066463A1 (en) * 2001-02-15 2002-08-29 Pharmacia & Upjohn Company 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2003002109A3 (en) * 2001-06-29 2004-05-27 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
CN100439360C (zh) * 2001-08-15 2008-12-03 法玛西雅厄普约翰美国公司 包括n-[2-(二乙氨基)乙基]-5-[(5-氟-2-氧代-3h-吲哚-3-亚基)甲基]-2,4-二甲基-1h-吡咯-3-甲酰胺的苹果酸盐的晶体、其制备方法和其组合物
US7435832B2 (en) 2001-08-15 2008-10-14 Pharmacia & Upjohn Company Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
EP3168218A1 (en) 2001-08-15 2017-05-17 Pharmacia & Upjohn Company LLC A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament
EP2332934B1 (en) 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
EA006445B9 (ru) * 2001-08-15 2017-02-28 Фармация Энд Апджон Компани Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции
EP2332934A1 (en) 2001-08-15 2011-06-15 Pharmacia & Upjohn Company LLC Chrystals including a malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
WO2003016305A1 (en) 2001-08-15 2003-02-27 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
HRP20040112B1 (en) * 2001-08-15 2012-03-31 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
US6777417B2 (en) 2001-09-10 2004-08-17 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors
WO2003022815A1 (en) * 2001-09-10 2003-03-20 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
WO2003031438A1 (en) * 2001-10-10 2003-04-17 Sugen, Inc. 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
EP1444204A4 (en) * 2001-10-22 2009-11-04 Univ New York State Res Found INHIBITORS OF PROTEIN KINASES AND PROTEINS PHOSPHATASES, METHODS OF IDENTIFICATION AND METHODS OF USE THEREOF
US7772216B2 (en) 2001-10-22 2010-08-10 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
EP1444204A1 (en) * 2001-10-22 2004-08-11 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
US8088768B2 (en) 2001-10-22 2012-01-03 The Research Foundation Of The State University Of New York Protein kinase and phosphatase inhibitors
EP1446117A2 (en) * 2001-10-26 2004-08-18 Sugen, Inc. Treatment of acute myeloid leukemia with indolinone compounds
EP1446117A4 (en) * 2001-10-26 2008-01-23 Sugen Inc TREATMENT OF ACUTE MYELOID LEUKEMIA USING INDOLINONE COMPOUNDS
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US6831175B2 (en) 2001-12-13 2004-12-14 Abbott Laboratories Kinase inhibitors
US7223783B2 (en) 2001-12-27 2007-05-29 Theravance, Inc. Indolinone derivatives
US6686362B2 (en) 2001-12-27 2004-02-03 Theravance, Inc. Indolinone derivatives
US7060703B2 (en) 2001-12-27 2006-06-13 Theravance, Inc. Indolinone derivatives
WO2003070725A2 (en) * 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Process for preparing indolinone derivatives
CN1308326C (zh) * 2002-02-15 2007-04-04 法马西亚和厄普乔恩公司 吲哚满酮衍生物的制备方法
WO2003070725A3 (en) * 2002-02-15 2004-01-15 Upjohn Co Process for preparing indolinone derivatives
US7119209B2 (en) 2002-02-15 2006-10-10 Pharmacia & Upjohn Company Process for preparing indolinone derivatives
WO2003097854A2 (en) * 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
WO2003097854A3 (en) * 2002-05-17 2009-08-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
EP1562600A2 (en) * 2002-11-15 2005-08-17 Sugen, Inc. Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
EP1562600A4 (en) * 2002-11-15 2008-06-25 Sugen Inc COMBINED ADMINISTRATION OF AN INDOLINONE HAVING CHEMOTHERAPEUTICS FOR CELL PROBLEMS
EP1581309A4 (en) * 2002-11-15 2009-07-29 Exelixis Inc KINASE MODULATORS
EP1581309A2 (en) * 2002-11-15 2005-10-05 Exelixis, Inc. Kinase modulators
WO2004045523A2 (en) * 2002-11-15 2004-06-03 Sugen, Inc. Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
CN100430060C (zh) * 2002-11-15 2008-11-05 苏根公司 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途
WO2004045523A3 (en) * 2002-11-15 2004-09-30 Sugen Inc Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
NL1024779C2 (nl) * 2002-11-15 2004-11-09 Sugen Gecombineerde toediening van een indolinon met een chemotherapeutisch middel voor celproliferatiestoornissen.
EP1599200A4 (en) * 2003-02-24 2007-02-07 Pharmacia & Upjohn Co Llc POLYMORPHS OF PYRROLE SUBSTITUTED PROTEIN KINASE 2-INDOLINONE COMPOUND INHIBITORS
EP2258699A1 (en) 2003-02-24 2010-12-08 Pharmacia & Upjohn Company LLC Polymorphs of a pyrrole-substituted 2-Indolinone protein kinase inhibitor
US7452913B2 (en) 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
EP1599200A2 (en) * 2003-02-24 2005-11-30 PHARMACIA & UPJOHN COMPANY Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
EP2476667A2 (en) 2003-02-26 2012-07-18 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
EP2359829A1 (en) 2003-04-29 2011-08-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
EP2826480A1 (en) 2003-04-29 2015-01-21 Boehringer Ingelheim International GmbH Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
EP2361626A1 (en) 2003-04-29 2011-08-31 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
EP2762475A1 (en) 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
US8058474B2 (en) 2003-11-11 2011-11-15 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
EP2277595A2 (en) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
WO2006004545A1 (en) * 2004-07-07 2006-01-12 Forskarpatent I Syd Ab Tamoxifen response in pre-and postmenopausal breast cancer patients
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
EP1814545A4 (en) * 2004-11-09 2009-06-10 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
JP2008519762A (ja) * 2004-11-09 2008-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP4917041B2 (ja) * 2004-11-09 2012-04-18 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US8101608B2 (en) 2004-11-09 2012-01-24 IRM LLC, a Delware Limited Corporation Compounds and compositions as protein kinase inhibitors
EP1814545A2 (en) * 2004-11-09 2007-08-08 Irm, Llc Compounds and compositions as protein kinase inhibitors
EP2361905A1 (en) 2005-05-18 2011-08-31 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
EP2364973A1 (en) 2005-05-18 2011-09-14 Array Biopharma, Inc. Heterocyclic inhibitors of MEK and Methods of use thereof
EP2266974A1 (en) 2005-05-23 2010-12-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts
EP2270000A1 (en) 2005-05-23 2011-01-05 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
EP1893194A1 (en) * 2005-05-26 2008-03-05 The Scripps Research Institute Enhanced indolinone based protein kinase inhibitors
EP1893194A4 (en) * 2005-05-26 2009-07-01 Scripps Research Inst IMPROVED PROTEIN KINASE HEMMER ON INDOLINON BASE
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
WO2007034272A1 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Solid salt forms of a pyrrole substituted 2-indolinone
EP2112148A1 (en) * 2005-09-19 2009-10-28 Pfizer Products Inc. Solid salt forms of a pyrrole substituted 2-indolinone
AU2006293644B2 (en) * 2005-09-19 2012-05-31 Zoetis Services Llc Solid salt forms of a pyrrole substituted 2-indolinone
US8987320B2 (en) 2005-09-19 2015-03-24 Zoetis Llc Solid salt forms of a pyrrole substituted 2-indolinone
US9290479B2 (en) 2005-09-19 2016-03-22 Zoetis Services Llc Solid salt forms of a pyrrole substituted 2-indolinone
US8211429B2 (en) 2005-11-08 2012-07-03 Genetech, Inc. Neuropilin antagonists
US8378080B2 (en) 2005-11-08 2013-02-19 Genentech, Inc. Neuropilin antagonists
US8795660B2 (en) 2005-11-08 2014-08-05 Genentech, Inc. Neuropilin antagonists
EP1971333A4 (en) * 2005-12-29 2009-05-20 Scripps Research Inst AMINO ACID DERIVATIVES OF PROTEIN KINASE INHIBITORS ON INDOLINONE BASE
EP1971333A2 (en) * 2005-12-29 2008-09-24 The Scripps Research Institute Amino acid derivatives of indolinone based protein kinase inhibitors
WO2007084786A1 (en) 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
EP2261223A1 (en) 2006-01-20 2010-12-15 Novartis AG Pyrimidine derivatives used as pi-3 kinase inhibitors
US7932262B2 (en) 2006-04-06 2011-04-26 Novartis Ag Quinazolines for PDK1 inhibition
EP2357202A1 (en) 2006-04-10 2011-08-17 AstraZeneca AB Targeted binding agents directed to Upar and uses thereof
WO2007124288A1 (en) 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of cdc7
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
WO2007134578A1 (de) * 2006-05-24 2007-11-29 Schebo Biotech Ag Neue indol-pyrrol-derivate zur behandlung proliferativer und inflammatorischer krankheiten
DE102006024834A1 (de) * 2006-05-24 2007-11-29 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendung
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP2420513A1 (en) 2006-08-03 2012-02-22 MedImmune Limited Targeted binding agents directed to PDGFR-alpha and uses thereof
EP2420514A1 (en) 2006-08-03 2012-02-22 MedImmune Limited Targeted binding agents directed to PDGFR-alpha and uses thereof
US8273741B2 (en) 2006-08-04 2012-09-25 Takeda Pharmaceutical Company Limited Imidazo-pyridazinyl compounds and uses thereof
US8034812B2 (en) 2006-08-04 2011-10-11 Takeda Pharmaceutical Company Limited Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof
US8044049B2 (en) 2006-08-04 2011-10-25 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
US9717736B2 (en) 2006-08-23 2017-08-01 Kudos Pharmaceuticals Limited Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US10034884B2 (en) 2006-08-23 2018-07-31 Kudos Pharmaceuticals Limited Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US7902189B2 (en) * 2006-08-23 2011-03-08 Astrazeneca Ab Compounds
US8101602B2 (en) 2006-08-23 2012-01-24 Kudos Pharmaceuticals, Ltd. Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US9102670B2 (en) 2006-08-23 2015-08-11 Kudos Pharmaceuticals Limited Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US8435985B2 (en) 2006-08-23 2013-05-07 Keith Menear Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
CN101511793B (zh) * 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US8039470B2 (en) 2006-09-15 2011-10-18 Tyrogenex, Inc. Kinase inhibitor compounds
US8524709B2 (en) 2006-09-15 2013-09-03 Tyrogenex, Inc. Kinase inhibitor compounds
US7683057B2 (en) 2006-09-15 2010-03-23 Tyrogenex, Inc. Kinase inhibitor compounds
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US8053461B2 (en) 2006-11-06 2011-11-08 Theravalues Corporation Oxindole derivative
EP2130829A1 (en) * 2006-11-06 2009-12-09 Theravalues Corporation Novel hydroxyindole derivative
EP2130829A4 (en) * 2006-11-06 2010-12-01 Theravalues Corp NEW HYDROXYINDOLE DERIVATIVE
US8084621B2 (en) 2006-12-04 2011-12-27 Jiangsu Simcere Pharmaceutical R&D Co. Ltd. 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US8329682B2 (en) 2007-05-14 2012-12-11 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
WO2008145398A1 (en) * 2007-06-01 2008-12-04 Pfizer Italia S.R.L. 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP2197878A2 (en) * 2007-09-06 2010-06-23 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
US9725444B2 (en) 2007-09-06 2017-08-08 Boston Biomedical, Inc Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
EP2197878A4 (en) * 2007-09-06 2012-02-08 Boston Biomedical Inc COMPOSITIONS OF KINASEINHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO KINASES
US8299106B2 (en) 2007-09-06 2012-10-30 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
EP3037419A1 (en) * 2007-09-06 2016-06-29 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
WO2009047563A1 (en) 2007-10-11 2009-04-16 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
WO2009067674A3 (en) * 2007-11-21 2009-08-27 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
WO2009067686A3 (en) * 2007-11-21 2009-11-12 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
WO2009067674A2 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
WO2009067686A2 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
EP2253629A1 (en) * 2007-11-21 2010-11-24 Teva Pharmaceutical Industries Ltd. Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
EP2690101A1 (en) 2007-12-19 2014-01-29 Genentech, Inc. 5-Anilinoimidazopyridines and Methods of Use
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
WO2009082687A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009100929A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
WO2009104021A2 (en) * 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
WO2009104021A3 (en) * 2008-02-21 2009-11-12 Generics [Uk] Limited Novel polymorphs and processes for their preparation
CN101983195A (zh) * 2008-02-21 2011-03-02 基因里克斯(英国)有限公司 新型多晶型物及其制备方法
EP2604603A1 (en) * 2008-03-06 2013-06-19 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide and methods for their preparation
WO2009109388A1 (en) * 2008-03-06 2009-09-11 Ratiopharm Gmbh Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
EA020067B1 (ru) * 2008-03-06 2014-08-29 Рациофарм Гмбх Полиморфная форма iii n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамида и способ её получения
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
US8466190B2 (en) 2008-04-16 2013-06-18 Natco Pharma Limited Polymorphic forms of Sunitinib base
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2292613A1 (en) * 2008-05-23 2011-03-09 Shanghai Institute of Pharmaceutical Industry Dihydroindolinone derivatives
EP2292613A4 (en) * 2008-05-23 2012-05-09 Shanghai Inst Pharm Industry DIHYDROINDOLINONDERIVATE
US8829039B2 (en) 2008-05-23 2014-09-09 Shanghai Institute Of Pharmaceutical Industry Dihydroindolinone derivatives
KR101375156B1 (ko) * 2008-05-23 2014-03-18 쟝수 치아타이 티안큉 파마수티컬 주식회사 디하이드로인돌리논 유도체들
WO2009157011A1 (en) * 2008-06-23 2009-12-30 Natco Pharma Limited Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
US8501962B2 (en) 2008-06-23 2013-08-06 Natco Pharma Limited Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
KR101629526B1 (ko) * 2008-06-24 2016-06-10 라티오팜 게엠베하 Ｎ-[2-(다이에틸아미노)에틸]-5-[(5-플루오로-1,2-다이하이드로-2-옥소-3ｈ-인돌-3-일리덴)메틸]-2,4-다이메틸-1ｈ-피롤-3-카복스아마이드를 포함하는 약학적 조성물
WO2009156128A1 (en) * 2008-06-24 2009-12-30 Ratiopharm Gmbh Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
KR20110022690A (ko) * 2008-06-24 2011-03-07 라티오팜 게엠베하 Ｎ-[2-(다이에틸아미노)에틸]-5-[(5-플루오로-1,2-다이하이드로-2-옥소-3ｈ-인돌-3-일리덴)메틸]-2,4-다이메틸-1ｈ-피롤-3-카복스아마이드를 포함하는 약학적 조성물
DE102008031038A1 (de) 2008-06-30 2009-12-31 Alexander Priv.-Doz. Dr. Dömling Sutent zur Anwendung in der Organtransplantation
CN102203085A (zh) * 2008-07-10 2011-09-28 基因里克斯(英国)有限公司 用于制备苹果酸舒尼替尼晶体形式的新方法
WO2010004339A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
US8618309B2 (en) 2008-07-24 2013-12-31 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
US9067915B2 (en) 2008-07-24 2015-06-30 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
WO2010023473A2 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
WO2010023474A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel polymorphs of sunitinib and processes for their preparation
WO2010023473A3 (en) * 2008-08-25 2010-05-14 Generics [Uk] Limited Crystalline form of sunitinib and processes for its preparation
EP2927244A1 (en) 2008-09-19 2015-10-07 MedImmune, LLC Antibodies directed to DLL4 and uses thereof
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
US8686023B2 (en) 2008-10-28 2014-04-01 Lek Pharmaceuticals D.D. Salts of sunitinib
WO2010055082A2 (en) 2008-11-13 2010-05-20 Lek Pharmaceuticals D.D. New crystal form of sunitinib malate
US8703967B2 (en) * 2008-11-13 2014-04-22 Lek Pharmaceuticals D.D. Crystal form of sunitinib malate
WO2010055082A3 (en) * 2008-11-13 2010-07-22 Lek Pharmaceuticals D.D. New crystal form of sunitinib malate
CN102272124B (zh) * 2008-11-13 2015-04-08 力奇制药公司 舒尼替尼苹果酸盐的新晶形
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
CN102272124A (zh) * 2008-11-13 2011-12-07 力奇制药公司 舒尼替尼苹果酸盐的新晶形
US20110275690A1 (en) * 2008-11-13 2011-11-10 Lek Pharmaceuticals D.D. New crystal form of sunitinib malate
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8143258B2 (en) 2008-12-02 2012-03-27 Takeda Pharmaceutical Company Limited Benzothiazole compounds useful for Raf inhibition
US8497274B2 (en) 2008-12-02 2013-07-30 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2010073034A1 (en) 2008-12-22 2010-07-01 Astrazeneca Ab Pyrimidine indole derivatives for treating cancer
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
EP2896618A1 (en) 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
WO2010076805A2 (en) 2009-01-02 2010-07-08 Hetero Research Foundation Novel polymorphs of sunitinib malate
US8329740B2 (en) 2009-01-02 2012-12-11 Hetero Research Foundation Polymorphs of sunitinib malate
EP3360879A1 (en) 2009-02-05 2018-08-15 ImmunoGen, Inc. Benzodiazepine derivatives as cytotoxic agents
WO2010091150A1 (en) 2009-02-05 2010-08-12 Immunogen, Inc. Novel benzodiazepine derivatives
EP3100745A1 (en) 2009-02-05 2016-12-07 Immunogen, Inc. Novel benzodiazepine derivatives
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010103094A1 (en) 2009-03-13 2010-09-16 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8785457B2 (en) 2009-03-13 2014-07-22 Cellzome Limited Pyrimidine derivatives as mTOR inhibitors
WO2010108665A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
WO2010118986A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2010136458A1 (en) * 2009-05-27 2010-12-02 Ratiopharm Gmbh Process for the preparation of n-[2-diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2264027A1 (en) 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
WO2011000905A1 (en) 2009-07-02 2011-01-06 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8541412B2 (en) 2009-08-04 2013-09-24 Les Laboratoires Servier Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
CN101987848A (zh) * 2009-08-04 2011-03-23 瑟维尔实验室 新的二氢吲哚酮化合物、它们的制备方法以及包含它们的药物组合物
EP2281822A1 (fr) * 2009-08-04 2011-02-09 Les Laboratoires Servier Nouveaux dérivés dihydroindolones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2011015728A1 (fr) * 2009-08-04 2011-02-10 Les Laboratoires Servier Nouveaux dérives dihydroindolones, leur procédé de préparation et les compositions pharmaceutiques qui les contienne
AU2010203305B2 (en) * 2009-08-04 2015-02-05 Les Laboratoires Servier New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
FR2948940A1 (fr) * 2009-08-04 2011-02-11 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR101309101B1 (ko) 2009-08-04 2013-09-16 르 라보레또레 쎄르비에르 디히드로인돌론 화합물，이들의 제조 방법 및 이들을 함유하는 약제학적 조성물
CN101987848B (zh) * 2009-08-04 2014-06-18 瑟维尔实验室 二氢吲哚酮化合物、它们的制备方法以及包含它们的药物组合物
AP2756A (en) * 2009-08-04 2013-09-30 Servier Lab New dihydroindolone compounds, a process for theirpreparation and pharmaceutical compositions containing them
US8133889B2 (en) 2009-08-04 2012-03-13 Les Laboratoires Servier Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
WO2011029807A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
US9242987B2 (en) 2009-10-20 2016-01-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
WO2011048082A1 (en) 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
EP3279215A1 (en) 2009-11-24 2018-02-07 MedImmune Limited Targeted binding agents against b7-h1
WO2011068233A1 (en) 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
WO2011101429A1 (en) 2010-02-22 2011-08-25 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
WO2011104555A3 (en) * 2010-02-25 2012-02-02 Generics [Uk] Limited Process for the preparation of sunitinib malate form i
WO2011107585A1 (en) 2010-03-04 2011-09-09 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
WO2011110199A1 (en) 2010-03-10 2011-09-15 Synthon B.V. A process for amidation of pyrrole carboxylate compounds
WO2011134831A1 (en) 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
WO2011154737A1 (en) 2010-06-11 2011-12-15 Astrazeneca Ab Morpholino pyrimidines and their use in therapy
WO2012000970A1 (en) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US8993249B2 (en) 2010-07-09 2015-03-31 Genentech, Inc. Anti-neuropilin antibodies and methods of use
WO2012016970A1 (en) 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor
WO2012022681A2 (en) 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
US8846953B2 (en) 2010-11-01 2014-09-30 Scinopharm Taiwan, Ltd. Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2012074761A1 (en) 2010-12-03 2012-06-07 Eli Lilly And Company Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
US20130331425A1 (en) * 2010-12-23 2013-12-12 Nektar Therapeutics Polymer-sunitinib conjugates
US10220020B2 (en) 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
US10682418B2 (en) 2010-12-23 2020-06-16 Nektar Therapeutics Polymer-sunitinib conjugates
US11419943B2 (en) 2010-12-23 2022-08-23 Nektar Therapeutics Polymer-sunitinib conjugates
US11406618B2 (en) 2010-12-23 2022-08-09 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
US9827326B2 (en) * 2010-12-23 2017-11-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
EP3666289A1 (en) 2011-02-15 2020-06-17 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
WO2012112708A1 (en) 2011-02-15 2012-08-23 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
EP3053600A1 (en) 2011-02-15 2016-08-10 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
WO2012128868A1 (en) 2011-02-15 2012-09-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
US9012461B2 (en) 2011-02-17 2015-04-21 Cancer Therapeutics Crc Pty Ltd FAK inhibitors
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
WO2012110774A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
US9120761B2 (en) 2011-02-17 2015-09-01 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
US9421205B2 (en) 2011-02-17 2016-08-23 Cancer Therapeutics CRC Pty Ltd. FAK inhibitors
WO2012136622A1 (en) 2011-04-04 2012-10-11 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US11598776B2 (en) 2011-06-03 2023-03-07 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
EP3409278A1 (en) 2011-07-21 2018-12-05 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US10875864B2 (en) 2011-07-21 2020-12-29 Sumitomo Dainippon Pharma Oncology, Inc. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
WO2013014162A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
US9175011B2 (en) 2011-09-21 2015-11-03 Cellzone Limited Morpholino substituted urea or carbamate derivatives as MTOR inhibitors
WO2013041652A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
WO2013050508A1 (en) 2011-10-07 2013-04-11 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors
US9242993B2 (en) 2011-10-07 2016-01-26 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013092854A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US9585850B2 (en) 2011-12-23 2017-03-07 Duke University Methods of treatment using arylcyclopropylamine compounds
CN102653521A (zh) * 2012-04-27 2012-09-05 首都师范大学 吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
WO2013185115A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014026243A1 (en) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP4074728A1 (en) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Modified peptides comprising an azido group
EP3584255A1 (en) 2012-08-31 2019-12-25 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US10766865B2 (en) 2012-10-16 2020-09-08 Sumitomo Dainippon Pharma Oncology, Inc. PKM2 modulators and methods for their use
WO2014093383A1 (en) 2012-12-14 2014-06-19 Arrien Pharmaceuticals Llc Substituted 1h-pyrrolo [2,3-b] pyridine and 1h-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors
EP3566750A2 (en) 2013-02-28 2019-11-13 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014160401A1 (en) * 2013-03-13 2014-10-02 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
EP3590932A1 (en) 2013-03-14 2020-01-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
US9453031B2 (en) 2013-03-15 2016-09-27 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Chemical entities
WO2014140644A1 (en) 2013-03-15 2014-09-18 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Chemical entities
EP3545956A1 (en) 2013-04-18 2019-10-02 Arrien Pharmaceuticals LLC 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h- pyrrolo[2,3-b]pyrazine dual itk and jak3 kinase inhibitors
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3336103A1 (en) 2013-07-10 2018-06-20 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP4000619A1 (en) 2013-12-06 2022-05-25 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
US10407393B2 (en) 2014-08-28 2019-09-10 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10822307B2 (en) 2014-08-28 2020-11-03 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10259791B2 (en) 2014-08-28 2019-04-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US11186547B2 (en) 2014-08-28 2021-11-30 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
EP3789027A1 (en) 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
US11090386B2 (en) 2015-02-25 2021-08-17 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
US11547705B2 (en) 2015-03-04 2023-01-10 Merck Sharp & Dohme Llc Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016198507A1 (en) 2015-06-09 2016-12-15 Monash University Aryl sulfonohydrazides
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US10835537B2 (en) 2015-08-03 2020-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of cancer
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2017132615A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
WO2017132617A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
WO2017174758A1 (en) 2016-04-07 2017-10-12 Imba - Institut Für Molekulare Biotechnologie Gmbh Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
US10544144B2 (en) 2016-06-06 2020-01-28 Shanghai Allist Pharmaceutical And Medical Technol Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
US10870694B2 (en) 2016-09-02 2020-12-22 Dana Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
WO2018106606A1 (en) 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
US10287253B2 (en) 2016-12-05 2019-05-14 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
US11173157B2 (en) 2016-12-05 2021-11-16 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019055909A1 (en) 2017-09-18 2019-03-21 Sutro Biopharma, Inc. ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
WO2019083365A1 (en) 2017-10-25 2019-05-02 Universiteit Leiden VECTORS OF ADMINISTRATION
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2019236496A1 (en) 2018-06-04 2019-12-12 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
US10857153B2 (en) 2018-06-04 2020-12-08 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
EP4335439A2 (en) 2018-06-20 2024-03-13 Ctxt Pty Ltd Compounds
WO2020002587A1 (en) 2018-06-28 2020-01-02 Ctxt Pty Limited Compounds
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
WO2020060944A1 (en) 2018-09-17 2020-03-26 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
US11530231B2 (en) 2018-12-04 2022-12-20 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
US11712433B2 (en) 2019-03-22 2023-08-01 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
WO2021037219A1 (zh) 2019-08-31 2021-03-04 上海奕拓医药科技有限责任公司 用于fgfr抑制剂的吡唑类衍生物及其制备方法
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2024006542A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates

Also Published As

Publication number Publication date
AR034118A1 (es) 2004-02-04
HUP0204433A3 (en) 2007-08-28
PL211834B1 (pl) 2012-06-29
CY2010004I2 (el) 2012-01-25
DE60129794T2 (de) 2007-12-06
WO2001060814A3 (en) 2002-01-24
NO2008019I2 (no) 2011-10-17
US6573293B2 (en) 2003-06-03
NL300430I2 (nl) 2010-04-01
IL151127A0 (en) 2003-04-10
BRPI0117360B8 (pt) 2021-07-06
US20070010569A1 (en) 2007-01-11
NL300430I1 (nl) 2010-03-01
CA2399358C (en) 2006-03-21
HUP0204433A2 (hu) 2003-04-28
LTPA2008002I1 (lt) 2019-02-25
ATE369359T1 (de) 2007-08-15
BRPI0108394B1 (pt) 2018-12-11
HRP20020751B1 (en) 2011-01-31
DE60129794D1 (de) 2007-09-20
PT1255752E (pt) 2007-10-17
JP2003523340A (ja) 2003-08-05
IS6501A (is) 2002-08-13
CN1439005A (zh) 2003-08-27
HK1051188A1 (en) 2003-07-25
BRPI0117360A2 (pt) 2012-01-24
CY1108032T1 (el) 2011-04-06
US20050176802A1 (en) 2005-08-11
LU91407I2 (fr) 2008-03-10
NO2008019I1 (no) 2009-01-12
BE2010C009I2 (US06573293-20030603-C00090.png) 2020-01-30
US20040063773A1 (en) 2004-04-01
CY2008004I2 (el) 2009-11-04
ME00415B (me) 2011-10-10
CY2008004I1 (el) 2009-11-04
MY130363A (en) 2007-06-29
NO2010002I2 (no) 2010-12-06
CR20120007A (es) 2012-02-24
IS2491B (is) 2009-01-15
UA73976C2 (uk) 2005-10-17
US20020156292A1 (en) 2002-10-24
US7125905B2 (en) 2006-10-24
NO20023831L (no) 2002-10-15
RS50444B (sr) 2010-03-02
SK287142B6 (sk) 2010-01-07
LU91407I9 (US06573293-20030603-C00090.png) 2018-12-28
CY2010004I1 (el) 2012-01-25
PE20011083A1 (es) 2001-10-26
SK13262002A3 (sk) 2003-03-04
AU2001239770B2 (en) 2006-01-05
CA2399358A1 (en) 2001-08-23
FR08C0002I1 (US06573293-20030603-C00090.png) 2008-03-21
FR08C0002I2 (fr) 2009-01-02
EA005996B1 (ru) 2005-08-25
KR20030003229A (ko) 2003-01-09
JP3663382B2 (ja) 2005-06-22
EP1255752B1 (en) 2007-08-08
YU61402A (sh) 2005-07-19
CZ20023081A3 (cs) 2003-02-12
HRP20020751A2 (en) 2004-12-31
NL300332I1 (nl) 2008-03-03
NO20023831D0 (no) 2002-08-13
NL300332I2 (nl) 2008-04-01
LTC1255752I2 (lt) 2019-08-26
NO2010002I1 (no) 2010-03-08
PL361209A1 (en) 2004-09-20
NO325532B1 (no) 2008-06-09
BR0108394A (pt) 2004-06-22
KR100713960B1 (ko) 2007-05-02
BRPI0117360B1 (pt) 2018-11-13
NZ520640A (en) 2005-04-29
EA200200862A1 (ru) 2003-02-27
DE122008000002I1 (de) 2008-04-17
CZ303705B6 (cs) 2013-03-27
NO2019005I1 (no) 2019-02-11
MXPA02008021A (es) 2004-04-05
CR20120009A (es) 2012-02-07
CN1329390C (zh) 2007-08-01
CO5280092A1 (es) 2003-05-30
BRPI0108394B8 (pt) 2021-05-25
BG65764B1 (bg) 2009-10-30
ES2290117T3 (es) 2008-02-16
BG107078A (bg) 2003-04-30
EP1255752A2 (en) 2002-11-13
DK1255752T3 (da) 2007-11-26
TWI306860B (en) 2009-03-01
SI1255752T1 (sl) 2007-12-31
AU3977001A (en) 2001-08-27
US7572924B2 (en) 2009-08-11
DE122010000004I1 (de) 2010-04-15
LU91657I2 (fr) 2010-05-03
HU228979B1 (en) 2013-07-29

Similar Documents

Publication Publication Date Title
US6573293B2 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1370554B1 (en) 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
AU2001239770A1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
US20040138269A1 (en) Substituted pyrroles as kinase inhibitors
US6635640B2 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2002247133A1 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
US6797725B2 (en) Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US20020028828A1 (en) (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-614/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2399358

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2399358

Country of ref document: CA

Ref document number: 151127

Country of ref document: IL

Ref document number: 520640

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00785/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/06469

Country of ref document: ZA

Ref document number: 200206469

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2001 560198

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008021

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027010706

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001914376

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001239770

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 107078

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2002-3081

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: P20020751A

Country of ref document: HR

Ref document number: 13262002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 200200862

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 018072690

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001914376

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027010706

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-3081

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 520640

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 520640

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001239770

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001914376

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2012-000007

Country of ref document: CR

Ref document number: CR2012-000009

Country of ref document: CR